Hypothalamic corticotrophin-releasing factor and norepinephrine mediate sympathetic and cardiovascular responses to acute intracarotid injection of tumour necrosis factor-α in the rat

Journal of Neuroendocrinology

Volumn 20, Issue 8, 2008, Pages 978-987

  Zhang, Z H ^a   Felder, Robert B ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Corticotrophin releasing factor; Paraventricular nucleus of hypothalamus; Tumour necrosis factor

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; NORADRENALIN; PHENYLEPHRINE; PRAZOSIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANTERIOR HYPOTHALAMUS; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; EVOKED RESPONSE; HEART RATE; HORMONE RELEASE; MALE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOTONIC AGENTS; CARDIOVASCULAR SYSTEM; CAROTID ARTERIES; CORTICOTROPIN-RELEASING HORMONE; HEART RATE; HYPOTHALAMUS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENTRICULAR; MALE; NEURONS; NOREPINEPHRINE; PHENYLEPHRINE; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHETIC NERVOUS SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48049095971     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01750.x     Document Type: Article

References (51)

1. Brown MR, Fisher LA. Corticotropin-releasing factor: Effects on the autonomic nervous system and visceral systems. Fed Proc 1985; 44: 243-248.
2. Fisher LA. Central actions of corticotropin-releasing factor on autonomic nervous activity and cardiovascular functioning. Ciba Found Symp 1993; 172: 243-253.
3. Chrousos GP. The stress response and immune function: Clinical implications. The 1999 Novera H. Spector Lecture. Ann NY Acad Sci 2000; 917: 38-67.
4. Dunn AJ. Cytokine activation of the HPA axis. Ann NY Acad Sci 2000; 917: 608-617.
5. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, Laflamme N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000; 223: 22-38.
6. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
7. Schiltz JC, Sawchenko PE. Signaling the brain in systemic inflammation: the role of perivascular cells. Front Biosci 2003; 8: S1321-S1329.
8. Kis B, Isse T, Snipes JA, Chen L, Yamashita H, Ueta Y, Busija DW. Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers. J Appl Physiol 2006; 100: 1392-1399.
9. Ericsson A, Arias C, Sawchenko PE. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 1997; 17: 7166-7179.
10. Cole RL, Sawchenko PE. Neurotransmitter regulation of cellular activation and neuropeptide gene expression in the paraventricular nucleus of the hypothalamus. J Neurosci 2002; 22: 959-969.
11. Guillaume V, Conte-Devolx B, Szafarczyk A, Malaval F, Pares-Herbute N, Grino M, Alonso G, Assenmacher I, Oliver C. The corticotropin-releasing factor release in rat hypophysial portal blood is mediated by brain catecholamines. Neuroendocrinology 1987; 46: 143-146.
12. Itoi K, Suda T, Tozawa F, Dobashi I, Ohmori N, Sakai Y, Abe K, Demura H. Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats. Endocrinology 1994; 135: 2177-2182.
13. Smagin GN, Swiergiel AH, Dunn AJ. Peripheral administration of interleukin-1 increases extracellular concentrations of norepinephrine in rat hypothalamus: Comparison with plasma corticosterone. Psychoneuroendocrinology 1996; 21: 83-93.
14. Sawchenko PE, Imaki T, Potter E, Kovacs K, Imaki J, Vale W. The functional neuroanatomy of corticotropin-releasing factor. Ciba Found Symp 1993; 172: 5-21.
15. Milner TA, Reis DJ, Pickel VM, Aicher SA, Giuliano R. Ultrastructural localization and afferent sources of corticotropin-releasing factor in the rat rostral ventrolateral medulla: Implications for central cardiovascular regulation. J Comp Neurol 1993; 333: 151-167.
16. Sawchenko PE. Evidence for differential regulation of corticotropin-releasing factor and vasopressin immunoreactivities in parvocellular neurosecretory and autonomic-related projections of the paraventricular nucleus. Brain Res 1987; 437: 253-263.
17. Loewy AD. Descending pathways to the sympathetic preganglionic neurons. Prog Brain Res 1982; 57: 267-277.
18. Mansi JA, Rivest S, Drolet G. Regulation of corticotropin-releasing factor type 1 (CRF1) receptor messenger ribonucleic acid in the paraventricular nucleus of rat hypothalamus by exogenous CRF. Endocrinology 1996; 137: 4619-4629.
19. Luo X, Kiss A, Makara G, Lolait SJ, Aguilera G. Stress-specific regulation of corticotropin releasing hormone receptor expression in the paraventricular and supraoptic nuclei of the hypothalamus in the rat. J Neuroendocrinol 1994; 6: 689-696.
20. Imaki T, Naruse M, Harada S, Chikada N, Imaki J, Onodera H, Demura H, Vale W. Corticotropin-releasing factor up-regulates its own receptor mRNA in the paraventricular nucleus of the hypothalamus. Brain Res Mol Brain Res 1996; 38: 166-170.
21. Rivest S, Laflamme N, Nappi RE. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci 1995; 15: 2680-2695.
22. Gibb J, Hayley S, Gandhi R, Poulter MO, Anisman H. Synergistic and additive actions of a psychosocial stressor and endotoxin challenge: circulating and brain cytokines, plasma corticosterone and behavioral changes in mice. Brain Behav Immun 2008; 22: 573-589.
23. Swiergiel AH, Li Y, Wei ZY, Dunn AJ. Effects of chlordiazepoxide on footshock- and corticotropin-releasing factor-induced increases in cortical and hypothalamic norepinephrine secretion in rats. Neurochem Int 2008; 52: 1220-1225.
24. Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: The role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003; 284: R916-R927.
25. American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol 2002; 283: R281-R283.
26. Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H423-H433.
27. Paxinos G, Watson C. The rat Brain is Stereotaxic Coordinates. Sydney: Academic Press, 1986.
28. Wei SG, Felder RB. Forebrain renin-angiotensin system has a tonic excitatory influence on renal sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2002; 282: H890-H895.
29. Dampney RA, Horiuchi J, Tagawa T, Fontes MA, Potts PD, Polson JW. Medullary and supramedullary mechanisms regulating sympathetic vasomotor tone. Acta Physiol Scand 2003; 177: 209-218.
30. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74: 323-364.
31. Schiltz JC, Sawchenko PE. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci 2002; 22: 5606-5618.
32. Zhang J, Rivest S. A functional analysis of EP4 receptor-expressing neurons in mediating the action of prostaglandin E2 within specific nuclei of the brain in response to circulating interleukin-1beta. J Neurochem 2000; 74: 2134-2145.
33. Ek M, Arias C, Sawchenko P, Ericsson-Dahlstrand A. Distribution of the EP3 prostaglandin E(2) receptor subtype in the rat brain: Relationship to sites of interleukin-1-induced cellular responsiveness. J Comp Neurol 2000; 428: 5-20.
34. Lacroix S, Vallieres L, Rivest S. C-fos mRNA pattern and corticotropin-releasing factor neuronal activity throughout the brain of rats injected centrally with a prostaglandin of E2 type. J Neuroimmunol 1996; 70: 163-179.
35. Hoffman WE, Schmid PG. Cardiovascular and antidiuretic effects of central prostaglandin E2. J Physiol 1979; 288: 159-169.
36. Ferri CC, Ferguson AV. Prostaglandin E2 mediates cellular effects of interleukin-1beta on parvocellular neurones in the paraventricular nucleus of the hypothalamus. J Neuroendocrinol 2005; 17: 498-508.
37. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
38. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
39. Piro M, Giubilato G, Pinnelli M, Giordano Sciacca P, Biasucci LM. Endothelium and inflammation. Panminerva Med 2005; 47: 75-80.
40. Granger JP. An emerging role for inflammatory cytokines in hypertension. Am J Physiol Heart Circ Physiol 2006; 290: H923-H924.
41. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-II10.
42. Pudil R, Pidrman V, Krejsek J, Gregor J, Tichy M, Andrys C, Drahosova M. Cytokines and adhesion molecules in the course of acute myocardial infarction. Clin Chim Acta 1999; 280: 127-134.
43. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-2059.
44. Vega GL. Obesity and the metabolic syndrome. Minerva Endocrinol 2004; 29: 47-54.
45. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004; 28: 87-91.
46. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5: 551-559.
47. O'Brien SM, Scott LV, Dinan TG. Cytokines: Abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397-403.
48. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001; 22: 1136-1143.
49. Guzzetti S, La Rovere MT, Pinna GD, Maestri R, Borroni E, Porta A, Mortara A, Malliani A. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur Heart J 2005; 26: 357-362.
50. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: 26L-40L.
51. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 1998; 98: 1329-1334.